Skip to main content

Table 4 Adjusted association between hepatic adverse events and episodes groups in the PA arm

From: Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

Parameters

aOR (95% CI) with hepatic adverse events;

Elevated ALT

LR-p: 0.041

Elevated AST

LR-p: 0.262

Elevated total bilirubin

LR-p: <0.001

Episode groups

   

 First treatment

1

1

1

 Retreatment

0.32 (0.14; 0.74) **

0.59 (0.25; 1.41)

2.09 (1.01; 4.29) *

Age

0.98 (0.90; 1.05)

0.93 (0.83; 1.04)

1.12 (1.07; 1.17) ***

Sex

   

 Female

1

1

1

 Male

1.47 (0.64; 3.38)

1.74 (0.69; 4.35)

1.10(0.57; 2.11)

  1. PA: pyronaridine-artesunate; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; LR-p: likelihood ratio test’s p-value; aOR: adjusted odds ratio; CI: Confidence interval;
  2. * p < 0.05; ** p < 0.01; *** p < 0.001
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us